NCT01755689 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults | Biotech Hunter

Enrollment

1,300

Participants

Timeline

Start Date

January 11, 2013

Primary Completion Date

April 29, 2014

Study Completion Date

April 29, 2014

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Meningococcal vaccine GSK134612

One dose administered intramuscularly (IM) in the deltoid of the right arm.

BIOLOGICAL

Cervarix®

Three doses administered intramuscularly (IM) in the deltoid of the left arm.

BIOLOGICAL

Boostrix®

One dose administered intramuscularly (IM) in the deltoid of the left arm.

Trial Locations (3)

GSK Investigational Site, Bangkok

GSK Investigational Site, Tartu

GSK Investigational Site, Santo Domingo